PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,775.00
Bid: 1,771.00
Ask: 1,771.50
Change: -8.50 (-0.48%)
Spread: 0.50 (0.028%)
Open: 1,773.50
High: 1,779.00
Low: 1,764.50
Prev. Close: 1,783.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-Dunelm's spooky "severe but plausible downside" scenario

Thu, 10th Sep 2020 11:50

Welcome to the home for real-time coverage of European equity markets brought to you by Reuters
stocks reporters. You can share your thoughts with Joice Alves (joice.alves@thomsonreuters.com)
and Julien Ponthus (julien.ponthus@thomsonreuters.com) in London and Danilo Masoni and Stefano
Rebaudo (stefano.rebaudo@thomsonreuters.com) in Milan.

DUNELM'S SPOOKY "SEVERE BUT PLAUSIBLE DOWNSIDE" SCENARIO (1039 GMT)

There's been quite a bit of disappointment to see the shares in British home furnishing
retailer Dunelm retreat this morning despite the encouraging sales achieved in the face
of the coronavirus pandemic.

Much of today's negative price action seems to be blamed on profit taking and on the
decision of Dunelm, a clear lockdown winner, to play it safe and to keep some cash for the
possible rainy days ahead.

"Despite strong current trading, a still uncertain outlook and 'prudent financial approach'
means the Board has chosen not to declare a final dividend for FY20 and management has not
issued FY21 PBT guidance", UBS analysts noted.

But another important part of Dunelm's earnings which might have spooked investors is the
retailer's assessment of what could go wrong.

"There is a fear stalking some companies", commented Neil Wilson at Markets.com, noting the
group's warning of a "severe but plausible" downside scenario which involves lockdowns over
Christmas.

Here's how Dunelm describes in its press release what could happen in a few months to its
business, but by extension to most European retailers:

"The 'severe but plausible downside' scenario is very conservative in assuming a further
national lockdown for ten weeks where our stores are no longer in the 'permitted' status and
where we are unable to offer our Click & Collect service.

We have also assumed that this national lockdown occurs in our peak Christmas and Winter
Sale trading period, with all of the Group's stores being required to shut for ten weeks in the
event of a second Covid-19 outbreak, on top of the downturn in the economy that is already
included in the central case, including potential Brexit-related disruption."

Yikes and merry Xmas everybody!

On a more positive note for Dunelm shareholders, the company "has been a clear relative
winner in the sector through the crisis, with possibly some lasting benefits from strong
customer acquisition," JP Morgan analysts believe.

Anyhow, here's how Dunelm has outperformed the FTSE 250 and how it's comparing with other
top retailers so far in 2020:

(Julien Ponthus)

*****

WHAT ABOUT A PE RATIO OF 100? (0955 GMT)

These days more than ever stock valuations seem to be a matter of how much cash is lying on
the sidelines as central banks are in a "whatever it takes" mood to pour liquidity in order to
avoid the adverse impact of the virus.

Jeroen Blokland, portfolio manager at Robeco, crunched some numbers to measure the
relationship between excess liquidity -- as the difference between money supply and nominal GDP
growth -- and the PE of the S&P 500 stocks.

He concludes that the PE ratio should be at a whooping 100, from around 28 these days.

"Obviously, this is not going to happen, also because nominal GDP growth is expected to
bounce back sharply," he says in a research note. "But it does point out that from a liquidity
perspective, valuation looks far from stretched".

The idea behind this is that if there is more money than needed for economic growth, excess
liquidity will find its way into the stock market.

(Stefano Rebaudo)

*****

BREXIT TURBO-CHARGES UK RISK PREMIA (0850 GMT)

Risk premia on UK assets are rising and will continue to do so as investors fear a messy
divorce with the European Union when Britain finally disentangles at the end of the year.

The European Union could take legal action under its divorce treaty with Britain if today’s
emergency talks do not reassure Brussels sufficiently that a proposed new British law will not
break previously agreed commitments.

An ABN Amro research note recalls that, inside the bond bank index, NatWest Group
over the last seven days staged "the largest underperformance, with their bail-in senior bonds
moving over 30bps wider."

Other names, such as Lloyds and Barclays have only performed a few basis
points better while HSBC, Santander UK and Standard Chartered have suffered a
20 basis points hit.

ABN Amro analysts anticipate that the Brexit negotiations will continue to produce negative
headlines with little achieved in the forthcoming weeks. "UK risks premiums are likely to stay
elevated for the remainder of this year," they say.

The bank index is at 79 basis points (bps) above the swap, roughly 29 bps wider than before
the coronavirus crisis and 158 bps tighter than the pandemic highs experienced in March.

(Stefano Rebaudo)

*****

OPENING SNAPSHOT: EUROPE WAVERS BEFORE THE ECB (0725 GMT)

We're off to an uncertain start in Europe this morning with investors awaiting for the ECB
to provide fresh direction with hints of more stimulus to soften the strength of the euro
against the dollar.

Major regional benchmarks were down slightly, following mild initial gains. The STOXX 600 is
last down 0.15%.

Pandemic-hit travel and leisure stocks are up 0.7% with British Airways owner IAG
up over 2% after launching a fully underwritten 2.7 billion euros capital increase to beef up
its balance sheet.

Games Workshop is up an outstanding 18% after saying trading in the three months to
end August topped its expectations.

UK listed housebuilders are doing well after an upbeat RICS survey showed that the
post-lockdown surge in the housing market intensified in August with prices hitting a 4-year
high. Taylor Wimpey and Barratt are both up more than 2%.

Italy's Nexi is up 5% after a report said the payment firms and SIA are close to
clearing a major hurdle to a potential merger.

Weaker oil and basic material stocks weighed. Tech was lower too.

(Danilo Masoni)

*****

ON OUR RADAR: EURO, IAG CAP RISE AND DEALMAKING (0644 GMT)

As we said the European Central Bank's policy meeting and any signals from the central bank
about future easing measures will be the key highlight for investors today.

The euro and bond markets are likely to be most sensitive to ECB news, but we'll be
keeping an eye on stocks too, especially on rate-sensitive sectors like banks.

Besides that, on the corporate front, it doesn't look there is any earth shattering news out
there so far.

This will be the first full session for investors to digest LVMH's decision to
walk away from its planned $16 billion takeover of Tiffany. LVMH was little changed on
the news yesterday.

Airlines, which have been heavily hit by travel restrictions adopted to fight the COVID
pandemic, continue to be under pressure. British Airways owner IAG launched a heavily
discounted 2.7 billion euros capital increase to beef up its finances. The good news here is
that it's fully underwritten.

GlaxoSmithKline said the U.S health regulator approved its lung disease drug Trelegy
Ellipta for expanded use, making it the first inhaler delivering three drugs at once to be
prescribed for uncontrolled asthma in the country.

In M&A, Equinor raised $1.1 billion by selling stakes in offshore wind power
development projects to BP, while in Italy, the government said it's ready to use its
vetting "golden" powers to ensure the Milan exchange is not sold to an unacceptable bidder.

Meanwhile in France, utility Suez reiterated its opposition to Veolia’s
offer for Engie's stake in Suez, saying it undervalued Suez.

Among smaller companies, share placement are expected to put under pressure Ferroamp
, Carasent, and Kojamo.

In earnings news, an upbeat outlook from Akzo Nobel could lift its shares, while Dixons
reported a 56% drop mobile phone in the 17 weeks to end-August.

(Danilo Masoni)

*****

MORNING CALL: IT'S ECB DAY (0530 GMT)

Regardless of whether it's going to have any big impact on markets today the focus is
squarely on the European Central Bank's policy meeting.

The consensus is that rates will remain unchanged although investors expect signals from the
central bank which could possibly weaken the euro.

On the background are still worries over rising Brexit risks and possible further turbulence
in tech stocks, and it may be little surprise that following yesterday's rebound in Europe and
the U.S., futures are giving mixed signals at the moment.

The Euro STOXX 500 futures are up 0.3%, FTSE 100 futures are down 0.3% and Wall Street
futures are moving flat to slightly higher.

(Danilo Masoni)

*****

More News
9 Oct 2023 07:42

LONDON BRIEFING: Metro Bank secures deal to shore up finances

(Alliance News) - Stocks in London are set to open higher on Monday as interest rate expectations held steady despite Friday's bumper US nonfarm payrolls report.

Read more
9 Oct 2023 07:20

GSK inks deal to promote shingles vaccine in China

(Sharecast News) - GSK has entered into a new exclusive vaccine partnership in China that will extend the availability of its shingle vaccine Shingrix, which will see the UK-listed group generate £2.5bn over the next three years.

Read more
8 Oct 2023 11:36

Sunday newspaper round-up: Renewi, Metro Bank, New homes

(Sharecast News) - Some of Renewi's major shareholders are divided as to whether the recycling company should engage with Australian suitor Macquarie. One major shareholder has told Renewi's board that it should not until Macquarie raised its £636m bid, but another top ten shareholder told The Sunday Times that it should talk to the Australian outfit anyways. Macquarie has until 26 October to make a firm offer. - The Sunday Times

Read more
6 Oct 2023 08:17

GSK raises £885.6m from Haleon share sale

(Sharecast News) - GSK said on Friday that it has sold 270m shares in Haleon - the consumer health business it spun off last year - raising around £885.6m.

Read more
6 Oct 2023 07:57

UPDATE: GSK banks GBP886 million from Haleon share sale

(Alliance News) - GSK PLC on Friday said it received GBP885.6 million in gross proceeds from its sale of shares in consumer healthcare spin-off Haleon PLC.

Read more
6 Oct 2023 07:46

LONDON BRIEFING: Wetherspoon swings to profit; UK house prices fall

(Alliance News) - Stocks in London are called to open higher on Friday, as investors eye a key nonfarm payroll reading in the US.

Read more
5 Oct 2023 15:47

UK dividends calendar - next 7 days

Friday 6 October 
Admiral Group PLCdividend payment date
Alfa Financial Software Holdings PLCspecial dividend payment date
Anglo-Eastern Plantations PLCdividend payment date
Blackrock World Mining Trust PLCdividend payment date
Cairn Homes PLCdividend payment date
Dalata Hotel Group PLCdividend payment date
Drax Group PLCdividend payment date
Glanbia PLCdividend payment date
GlobalData PLCdividend payment date
Goodwin PLCdividend payment date
Greggs PLCdividend payment date
Intertek Group PLCdividend payment date
Irish Continental Group PLCdividend payment date
JPMorgan American Investment Trust PLCdividend payment date
JPMorgan Global Growth & Income PLCdividend payment date
Land Securities Group PLCdividend payment date
Personal Assets Trust PLCdividend payment date
Quartix Technologies PLCdividend payment date
Serco Group PLCdividend payment date
Walker Crips Group PLCdividend payment date
Warehouse REIT PLCdividend payment date
Zotefoams PLCdividend payment date
Monday 9 October 
Henderson Smaller Cos Investment Trust PLCdividend payment date
LondonMetric Property PLCdividend payment date
Tuesday 10 October 
LSL Property Services PLCdividend payment date
Wednesday 11 October 
Assura PLCdividend payment date
Rathbones Group PLCdividend payment date
Thursday 12 October 
Blackrock Latin American Investment Trust PLCex-dividend payment date
Breedon Group PLCex-dividend payment date
Diageo PLCdividend payment date
GSK PLCdividend payment date
Howden Joinery Group PLCex-dividend payment date
i3 Energy PLCex-dividend payment date
Invesco Bond Income Plus Ltdex-dividend payment date
JPMorgan Asia Growth & Income PLCex-dividend payment date
JPMorgan Mid Cap Investment Trust PLCex-dividend payment date
Kingfisher PLCex-dividend payment date
MP Evans Group PLCex-dividend payment date
Macfarlane Group PLCdividend payment date
North American Income Trust PLCex-dividend payment date
Oxford Instruments PLCdividend payment date
Persimmon PLCex-dividend payment date
Personal Group Holdings PLCex-dividend payment date
Primary Health Properties PLCex-dividend payment date
Ruffer Investment Co Ltdex-dividend payment date
Senior PLCex-dividend payment date
Spirax-Sarco Engineering PLCex-dividend payment date
Strategic Equity Capital PLCex-dividend payment date
Supermarket Income REIT PLCex-dividend payment date
Taylor Wimpey PLCex-dividend payment date
Tesco PLCex-dividend payment date
TT Electronics PLCdividend payment date
WPP PLCex-dividend payment date
XP Power Ltddividend payment date
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
3 Oct 2023 18:19

IN BRIEF: GSK's Jemperli approved in UK for endometrial cancer

GSK PLC - London-based pharmaceutical company - On Monday, announces that the UK Medicines & Health Products Regulatory Agency has authorised a new indication for Jemperli, also known as dostarlimab. The drug is used as a treatment for some types of endometrial cancer and an be used to treat patients that have a tumour abnormality called mismatch repair deficient/microsatellite instability-high when the cancer is at an advanced stage when first diagnosed or has returned after previous treatment. It is now authorised to be used together with chemotherapy to slow the progression of these cancers. GSK says it is the first medicine licensed as first line treatment for primary advanced or recurrent endometrial cancer.

Read more
3 Oct 2023 11:59

LONDON MARKET MIDDAY: HSBC and StanChart help FTSE 100 outperform

(Alliance News) - London's FTSE 100 grew in confidence as Tuesday morning progressed, going into the afternoon in the green and outperforming European peers.

Read more
25 Sep 2023 09:13

LONDON BROKER RATINGS: Jefferies raises AstraZeneca to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
25 Sep 2023 08:37

TOP NEWS: GSK's Arexvy vaccine approved for adults over 60 in Japan

(Alliance News) - GSK PLC on Monday said the Japan Ministry of Health, Labour & Welfare has approved Arexvy for adults over 60.

Read more
25 Sep 2023 07:28

GSK's RSV vaccine gets approval in Japan

(Sharecast News) - GSK announced on Monday that its vaccine, Arexvy, has received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for preventing respiratory syncytial virus (RSV) disease in adults aged 60 and over.

Read more
19 Sep 2023 09:30

GSK says new HIV PrEP medication authorised by European Commission

(Alliance News) - GSK PLC on Tuesday said the European Commission has authorised ViiV Healthcare's "superior" drug Apretude to reduce the risk of sexually acquired HIV-1 infection.

Read more
18 Sep 2023 09:40

LONDON BROKER RATINGS: Jefferies likes Energean; JPMorgan raises IDS

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
18 Sep 2023 07:57

LONDON BRIEFING: Phoenix Group hails "impressive" first-half

(Alliance News) - Stocks in London are called lower on Monday, as investors focus on the week's upcoming central bank decisions.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.